GSK PLC said Friday that China has approved a two-dose schedule for its Cervarix vaccine for girls aged nine to 14.
The healthcare company said that the vaccine is against certain types of cancer-causing human papillomavirus. In 2020, there were 110,000 new cases of cervical cancer and 59,000 deaths due to the disease in China, it said.
The authorization of the two-dose regime by the Chinese regulator adds to approvals in around 100 countries. The three-dose schedule remains on the label for girls and women aged 15-45 years in China, GSK said.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments